The role of noncoding RNAs in rare gynecological cancers.

Gynecological cancers are cancers that begin in the female reproductive organs. Gynecological cancer is the second most common cancer type among women and has become a global health burden for the female population. More than 50 % of all gynecological cancers can be defined as rare cancers. Three main types of noncoding RNAs (ncRNAs), namely, microRNAs (miRNAs), long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs), play crucial regulatory roles in physiological and pathological processes. Increasing evidence has revealed that ncRNAs closely participate in gynecological cancers. In this review, we focus on the role of ncRNAs in rare gynecological cancers. We first introduce the definitions, classifications, epidemiological characteristics, prognoses and treatments of rare gynecological cancers. Next, we summarize the differentially expressed ncRNAs and the molecular mechanisms underlying ncRNA connections to tumorigenesis, metastasis, chemoresistance, and recurrence. Finally, we highlight the potential applications of ncRNAs as diagnostic and prognostic biomarkers and therapeutic targets.

• Publication year

  2025

• Venue

  Biochimica et biophysica acta. Reviews on cancer

• Publication date

  2025-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.bbcan.2025.189362PMID 40451392
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Invasion and metastasis in cancer: molecular insights and therapeutic targets

  2025cited by this paper
• CRISPR integrated biosensors: A new paradigm for cancer detection.

  2025cited by this paper
• Advances in CRISPR/Cas13a-based biosensors for non-coding RNA detection.

  2025cited by this paper
• The Application of Non-Coding RNAs as Biomarkers, Therapies, and Novel Vaccines in Diseases

  2025cited by this paper
• Unravelling the epigenetic based mechanism in discovery of anticancer phytomedicine: Evidence based studies.

  2025cited by this paper
• Nanotechnology-leveraged CRISPR/Cas systems: icebreaking in trace cancer-related nucleic acids biosensing

  2025cited by this paper
• Non-coding RNAs: emerging biomarkers and therapeutic targets in cancer and inflammatory diseases

  2025cited by this paper
• Advancements in the Understanding of Small-Cell Neuroendocrine Cervical Cancer: Where We Stand and What Lies Ahead

  2024cited by this paper
• LncRNA SNHG12 promotes cell proliferation and inhibits apoptosis of granulosa cells in polycystic ovarian syndrome by sponging miR-129 and miR-125b

  2024cited by this paper
• Non-Coding RNA-Targeted Therapy: A State-of-the-Art Review

  2024cited by this paper
• The Role of Noncoding RNA in the Transmission and Pathogenicity of Flaviviruses

  2024cited by this paper
• Discovery of prognostic lncRNAs in colorectal cancer using spatial transcriptomics

  2024cited by this paper
• Competing endogenous RNAs (ceRNAs) and drug resistance to cancer therapy

  2024cited by this paper
• Cancer, metastasis, and the epigenome

  2024cited by this paper
• Current status of in vitro models for rare gynaecological cancer research.

  2024cited by this paper
• Exploring the role of noncoding RNAs in cancer diagnosis, prognosis, and precision medicine

  2024cited by this paper
• Chirurgische Therapie im Rezidivfall bei intraabdominellen muzinösen Neoplasien

  2023cited by this paper
• Molecular Biology of Pediatric and Adult Ovarian Germ Cell Tumors: A Review

  2023cited by this paper
• Metformin inhibits ovarian granular cell pyroptosis through the miR-670-3p/NOX2/ROS pathway

  2023cited by this paper
• β-catenin-driven differentiation is a tissue-specific epigenetic vulnerability in adrenal cancer.

  2023cited by this paper
• The Role of MicroRNAs in Uterine Leiomyosarcoma Diagnosis and Treatment

  2023cited by this paper
• Clinical characteristics and survival outcomes in patients with primary ovarian carcinoid: A historical cohort study

  2023cited by this paper
• Determining a minimum data set for reporting clinical and radiologic data for pseudomyxoma peritonei

  2023cited by this paper
• miR‑146a‑5p and miR‑191‑5p as novel diagnostic marker candidates for ovarian clear cell carcinoma

  2023cited by this paper
• Genomic and Molecular Characteristics of Ovarian Carcinosarcoma

  2023cited by this paper
• Non-coding RNAs in disease: from mechanisms to therapeutics

  2023cited by this paper
• Synergy of the microRNA Ratio as a Promising Diagnosis Biomarker for Mucinous Borderline and Malignant Ovarian Tumors

  2023cited by this paper
• Frontiers of Ovarian Carcinosarcoma

  2023cited by this paper
• MicroRNA Landscape in Endometrial Carcinomas in an Asian population: Unraveling Subtype-Specific Signatures

  2023cited by this paper
• Sertoli–Leydig cell tumor: a clinicopathological analysis in a comprehensive, national cohort

  2023cited by this paper
• Targeting oncogenic microRNAs from the miR-371~373 and miR-302/367 clusters in malignant germ cell tumours causes growth inhibition through cell cycle disruption

  2023cited by this paper
• Determinants of Outcome with Reoperative Surgery for Pseudomyxoma Peritonei in 186 Patients

  2023cited by this paper
• Current Advances in Cellular Approaches for Pathophysiology and Treatment of Polycystic Ovary Syndrome

  2023cited by this paper
• A Comprehensive Analysis of the PI3K/AKT Pathway: Unveiling Key Proteins and Therapeutic Targets for Cancer Treatment

  2023cited by this paper
• Spatial transcriptomics in human biomedical research and clinical application

  2023cited by this paper
• Chirurgische Therapie des Pseudomyxoma-peritonei-Syndroms – zytoreduktive Chirurgie und hypertherme intraperitoneale Chemotherapie

  2023cited by this paper
• Transcriptomic analyses of ovarian clear-cell carcinoma with concurrent endometriosis

  2023cited by this paper
• Small cell neuroendocrine carcinoma of the cervix: From molecular basis to therapeutic advances

  2023cited by this paper
• DICER1 RNase IIIb domain mutations trigger widespread miRNA dysregulation and MAPK activation in pediatric thyroid cancer

  2023cited by this paper
• Stage, treatment and survival of low‐grade serous ovarian carcinoma in the Netherlands: A nationwide study

  2023cited by this paper
• The genetic profile and molecular subtypes of human pseudomyxoma peritonei and appendiceal mucinous neoplasms: a systematic review

  2023cited by this paper
• Pediatric primary extra-ovarian Sertoli Leydig cell tumor of the retroperitoneum

  2023cited by this paper
• Non-coding RNAs in human health and disease: potential function as biomarkers and therapeutic targets

  2023cited by this paper
• Low-Grade Serous Carcinoma of the Ovary: The Current Status

  2022cited by this paper
• Preoperative serum microRNAs as potential prognostic biomarkers in ovarian clear cell carcinoma

  2022cited by this paper
• Descriptive epidemiology of gynaecological cancers in southern Ethiopia: retrospective cross-sectional review

  2022cited by this paper
• Clinical and paraclinical features, outcome, and prognosis of ovarian granulosa cell tumor: A retrospective study of 28 Vietnamese women

  2022cited by this paper
• Cancer-Specific miRNAs Extracted from Tissue-Exudative Extracellular Vesicles in Ovarian Clear Cell Carcinoma

  2022cited by this paper
• Organoids

  2022cited by this paper
• Diagnostic value of circN4BP2L2 in type I and type II epithelial ovarian cancer

  2022cited by this paper
• Mutant p53 in cancer: from molecular mechanism to therapeutic modulation

  2022cited by this paper
• MicroRNA and Metabolic Profiling of a Primary Ovarian Neuroendocrine Carcinoma Pulmonary-Type Reveals a High Degree of Similarity with Small Cell Lung Cancer

  2022cited by this paper
• Adult-type granulosa cell tumor of the ovary.

  2022cited by this paper
• Ovarian Germ Cell Tumors: Pictorial Essay

  2022cited by this paper
• Advancements in Low-Grade Serous Carcinoma of the Ovary and Peritoneum

  2022cited by this paper
• Small cell neuroendocrine carcinoma of the cervix: Analysis of prognostic factors and patterns of metastasis

  2022cited by this paper
• Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22)

  2022cited by this paper
• Plasma circN4BP2L2 is a promising novel diagnostic biomarker for epithelial ovarian cancer

  2022cited by this paper
• Small Cell (Neuroendocrine) Carcinoma of the Cervix: An Analysis for 19 Cases and Literature Review

  2022cited by this paper
• Exosomal MicroRNA as Biomarkers for Diagnosing or Monitoring the Progression of Ovarian Clear Cell Carcinoma: A Pilot Study

  2022cited by this paper
• Targeting non-coding RNAs to overcome cancer therapy resistance

  2022cited by this paper
• Primary ovarian carcinoid arising in associated mature cystic teratoma

  2022cited by this paper
• Clinicopathological Determinants of Recurrence Risk and Survival in Mucinous Ovarian Carcinoma

  2021cited by this paper
• Expression of the chrXq27.3 miRNA cluster in recurrent ovarian clear cell carcinoma and its impact on cisplatin resistance

  2021cited by this paper
• Serum tumour markers in germ cell tumours: from diagnosis to cure.

  2021cited by this paper
• GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic Tumors—Current Challenges and Future Directions

  2021cited by this paper
• miR-3188 Regulates proliferation and apoptosis of granulosa cells by targeting KCNA5 in the polycystic ovary syndrome.

  2021cited by this paper
• Extracellular miRNAs as Predictive Biomarkers for Glypican-3-Derived Peptide Vaccine Therapy Response in Ovarian Clear Cell Carcinoma

  2021cited by this paper
• Silencing of lncRNA UCA1 inhibited the pathological progression in PCOS mice through the regulation of PI3K/AKT signaling pathway

  2021cited by this paper
• Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments

  2021cited by this paper
• Non-coding RNA in cancer

  2021cited by this paper
• Low-grade serous epithelial ovarian cancer: a comprehensive review and update for radiologists

  2021cited by this paper
• MicroRNA-21 inhibits ovarian granulosa cell proliferation by targeting SNHG7 in premature ovarian failure with polycystic ovary syndrome.

  2021cited by this paper
• Progress in the management of ovarian granulosa cell tumor: A review

  2021cited by this paper
• Vulvar Melanoma: Molecular Characteristics, Diagnosis, Surgical Management, and Medical Treatment

  2021cited by this paper
• Ovarian Sertoli-Leydig cell tumours: A systematic review of relapsed cases.

  2021cited by this paper
• Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes.

  2021cited by this paper
• LncRNA TMPO-AS1 suppresses the maturation of miR-335-5p to participate in polycystic ovary syndrome

  2021cited by this paper
• Therapeutic Management of Rare Primary Ovarian Neoplasms: Carcinosarcoma, Leiomyosarcoma, Melanoma and Carcinoid

  2021cited by this paper
• LncRNA GAS5 inhibits the proliferation and invasion of ovarian clear cell carcinoma via the miR‐31‐5p/ARID1A axis

  2021cited by this paper
• Battling Chemoresistance in Cancer: Root Causes and Strategies to Uproot Them

  2021cited by this paper
• Leiomyosarcoma of the Uterus: A Rare Diagnosis

  2021cited by this paper
• (In)Distinctive Role of Long Non-Coding RNAs in Common and Rare Ovarian Cancers

  2021cited by this paper
• Primary neuroendocrine tumors of the ovary: Management and outcomes

  2021cited by this paper
• microRNA-194 is increased in polycystic ovary syndrome granulosa cell and induce KGN cells apoptosis by direct targeting heparin-binding EGF-like growth factor

  2021cited by this paper
• Endometrial cancer

  2021cited by this paper
• Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study

  2020cited by this paper
• LncRNA GAS5 is upregulated in polycystic ovary syndrome and regulates cell apoptosis and the expression of IL-6

  2020cited by this paper
• Clear cell carcinoma of the ovary: a clinical and molecular perspective

  2020cited by this paper
• Differential Diagnosis of Small Cell Carcinoma of the Ovary or Ovarian Metastases of Small Cell Carcinoma of the Lung: A Case Report and Review of the Literature

  2020cited by this paper
• Rare ovarian tumors: an update on diagnosis and treatment

  2020cited by this paper
• Immunohistochemical and Molecular Characterization of Endometrial Stromal Sarcomas

  2020cited by this paper
• The role of noncoding RNAs in epithelial cancer

  2020cited by this paper
• Not all cancers are created equal: Tissue specificity in cancer genes and pathways.

  2020cited by this paper
• Low-grade serous ovarian cancer: State of the science.

  2020cited by this paper
• Primary malignant ovarian carcinoid; management and outcomes.

  2020cited by this paper
• Long non‐coding RNA SNHG6 promotes cell proliferation and migration through sponging miR‐4465 in ovarian clear cell carcinoma

  2019cited by this paper
• Global incidence comparisons and trends in ovarian germ cell tumors by geographic region in girls, adolescents and young women: 1988-2012.

  2019cited by this paper
• microRNA-126 Is a Tumor Suppressor of Granulosa Cell Tumor Mediated by Its Host Gene EGFL7

  2019cited by this paper
• Extracellular Vesicles: Exosomes and Microvesicles, Integrators of Homeostasis.

  2019cited by this paper

• No citing papers are available for this paper.